In this issue of the ARCHIVES, the 2 studies by Bordley et al1 and King et al2 clearly point out the conundrums, confusion, and concerns regarding the currently available methods of diagnosis and testing as well as pharmacologic therapies for bronchiolitis in young children. These well-designed reviews conclude that the present indications for testing and efficacy of the therapeutic modalities discussed are insufficient. The results produce 2 major questions: Why is no benefit or efficacy demonstrated, and where do we go from here?
Hall CB. Managing Bronchiolitis and Respiratory Syncytial VirusFinding the Yellow Brick Road. Arch Pediatr Adolesc Med. 2004;158(2):111-112. doi:10.1001/archpedi.158.2.111